Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, +17

The Lancet Oncology

OncologyMetronomic TherapyGynecologyNiraparib MonotherapyLate-line Treatment +4

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

Jacalyn Rosenblatt, Richard M. Stone, Lynne Uhl, +24

Science Translational Medicine

Lenalidomide enhances anti-myeloma cellular immunity

Katarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, +12

Cancer Immunology Immunotherapy

Hematological MalignancyHematologyImmunologyAnti-myeloma Cellular ImmunityAutoimmunity +4

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells

Britta Will, Tanya Siddiqi, Meritxell Alberich-Jordà, +7

Blood

MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, +16

Cancer Research

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, +8

Clinical Lymphoma Myeloma & Leukemia

The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies

Parameswaran Hari, Dorothy Romanus, Katarina Luptakova, +6

Journal of Geriatric Oncology

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma

Salvia Jain, Dina Stroopinsky, Yin Li, +15

Blood

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).

Ajay K. Nooka, Keith Stockerl‐Goldstein, Hang Quach, +15

Journal of Clinical Oncology

ImmunologyImmune RegulationImmunoeditingPharmacotherapyImmunotherapeutics +20

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <scp>MUC</scp>1

Michal Bar‐Natan, Dina Stroopinsky, Katarina Luptakova, +15

British Journal of Haematology

ImmunologyCell DeathImmunotherapyTumor BiologyMyeloid Neoplasia +17